CB-011, an Allogeneic Anti-BCMA CAR-T cell Therapy with Immune Cloaking, for Patients with relapsed/refractory Multiple Myeloma (r/r MM): Dose Escalation Results from the Cammouflage Phase 1 Trial

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Adriana Rossi, Luciano J. Costa, William B. Clark, Daniel Sherbenou, David S. Siegel, Manisha Bhutani, Faiz Anwer, Sham Mailankody, James Essell, Jay Spiegel, Donna Marcy, Kellie McWilliams
+22 more Ine-Mari Bornman, Chris Holland, Shally Chung, Ashraf Garrett, Kenneth V. Hyland, Jeffrey Hellman, J Rattan, Alexandra M. Lied, Karen Lyle, Paul D. Donohoue, Elizabeth Garner, Pingping Mao, Eric Stawiski, Justin Skoble, Elaine Alambra, Enrique Zudaire, Tonia Nesheiwat, Tina Albertson, Maria do Socorro Oliveira Portella, Wellington Mendes, Sundar Jagannath, Binod Dhakal
DOI: 10.1016/j.jtct.2026.02.037
Cited by: 2

Fields of Study & Subjects

CAR-T cell therapy research Cutaneous lymphoproliferative disorders research Multiple Myeloma Research and Treatments

Publication details

Journal / source
Transplantation and Cellular Therapy
Publisher
Elsevier BV
Volume
32
Issue
3
Pages
S17–S18
Publication date
1 March 2026
Language
EN